Cytosorbents Corp
NASDAQ:CTSO

Watchlist Manager
Cytosorbents Corp Logo
Cytosorbents Corp
NASDAQ:CTSO
Watchlist
Price: 0.6801 USD -0.03% Market Closed
Market Cap: 42.7m USD

Cytosorbents Corp
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cytosorbents Corp
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Cytosorbents Corp
NASDAQ:CTSO
Cash from Operating Activities
-$10m
CAGR 3-Years
29%
CAGR 5-Years
-3%
CAGR 10-Years
-1%
Becton Dickinson and Co
NYSE:BDX
Cash from Operating Activities
$3.4B
CAGR 3-Years
9%
CAGR 5-Years
-1%
CAGR 10-Years
7%
Boston Scientific Corp
NYSE:BSX
Cash from Operating Activities
$4.6B
CAGR 3-Years
57%
CAGR 5-Years
25%
CAGR 10-Years
21%
Stryker Corp
NYSE:SYK
Cash from Operating Activities
$4.8B
CAGR 3-Years
23%
CAGR 5-Years
12%
CAGR 10-Years
18%
Abbott Laboratories
NYSE:ABT
Cash from Operating Activities
$9.1B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
10%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash from Operating Activities
$3B
CAGR 3-Years
22%
CAGR 5-Years
16%
CAGR 10-Years
16%
No Stocks Found

Cytosorbents Corp
Glance View

Market Cap
42.7m USD
Industry
Health Care

CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Monmouth Junction, New Jersey and currently employs 221 full-time employees. The company went IPO on 2005-06-17. The firm is engaged in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via its polymer adsorption technology. The firm's lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy and pancreatitis. Its other products include animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. The firm's product candidates under development includes CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent and porous polymer beads.

CTSO Intrinsic Value
2.9831 USD
Undervaluation 77%
Intrinsic Value
Price

See Also

What is Cytosorbents Corp's Cash from Operating Activities?
Cash from Operating Activities
-10m USD

Based on the financial report for Sep 30, 2025, Cytosorbents Corp's Cash from Operating Activities amounts to -10m USD.

What is Cytosorbents Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-1%

Over the last year, the Cash from Operating Activities growth was 46%. The average annual Cash from Operating Activities growth rates for Cytosorbents Corp have been 29% over the past three years , -3% over the past five years , and -1% over the past ten years .

Back to Top